Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
NCT ID: NCT00081094
Last Updated: 2013-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
31 participants
INTERVENTIONAL
2003-09-30
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying how well carbon-11 acetate PET and fludeoxyglucose F 18 PET work in detecting cancer in patients with liver cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FDGal PET/CT to Detect Hepatocellular Carcinoma
NCT02899325
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
NCT02379377
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
NCT01395030
[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
NCT02695628
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
NCT02088775
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PET scan (FDG-PET & 11C-acetate-PET)
Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
18F-Fluorodeoxyglucose-PET (FDG-PET)
11Carbon-Acetate-PET
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-Fluorodeoxyglucose-PET (FDG-PET)
11Carbon-Acetate-PET
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* AFP \> 200 mg/dL;
* A contrast-enhancing tumor mass (\>1 cm) by CT or MRI; or
* A tumor mass confirmed by arteriography.
* Patient must provide written informed consent and have completed conventional imaging and staging before initiation of PET imaging.
EXCLUSION:
* Pediatric patients under the age of 18 will be excluded from consideration from this study.
* Patients with a known prior malignancy (with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix) within 5 years will be excluded from entry into the study. However, patients with a prior HCC thought to have a new primary or recurrent HCC are eligible.
* Pregnant and breastfeeding patients.
* Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Washington University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William C. Chapman, M.D.
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Washington University School of Medicine
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WU-03-0771
Identifier Type: -
Identifier Source: secondary_id
CDR0000358907
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.